WALTHAM, Mass. — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced a new collaboration with OpenAI to expand the role of artificial intelligence across its global operations. The partnership aims to improve the speed and success rate of drug development, helping biopharma customers deliver new medicines to patients faster and more cost-effectively.
Through the initiative, Thermo Fisher will integrate OpenAI’s APIs into key areas of its business, including product development, service delivery, customer engagement, and operational efficiency. The collaboration is designed to accelerate scientific innovation, enhance productivity, and simplify complex workflows across the life sciences sector.
One of the first focus areas will be Thermo Fisher’s PPD clinical research business, where OpenAI’s advanced capabilities will be used to reduce clinical trial cycle times and speed the delivery of new therapies. The companies will also use AI to help identify therapies unlikely to succeed earlier in the process, allowing customers to reallocate resources toward more promising candidates.
In addition, OpenAI’s technology will be embedded into Thermo Fisher’s Accelerator Drug Development solution—an end-to-end platform that supports customers from early-stage development through clinical manufacturing, supply, and commercialization—to provide greater speed, scalability, and simplicity.
Thermo Fisher also plans to roll out ChatGPT Enterprise to its employees, enabling teams to gain hands-on experience and confidence using AI tools in everyday work.
“AI is shaping the future of science. And when combined with our Mission to enable our customers to make the world healthier, cleaner and safer, it is a powerful catalyst to accelerate scientific advancement,” said Marc Casper, Chairman, President and Chief Executive Officer of Thermo Fisher Scientific. “With OpenAI, we’re further embedding AI across our operations, products and services. Together, we’re building an ecosystem that accelerates scientific breakthroughs and delivers impact for customers, patients and society.”
“Thermo Fisher plays a massive role in advancing science, and together we have an opportunity to accelerate how medicine can reach more people,” said Brad Lightcap, Chief Operating Officer at OpenAI. “With OpenAI directly powering Thermo Fisher workflows, frontier AI can help cut through complexity, speed up breakthroughs, and bring real impact to patients’ lives.”
